VMAT2


Also found in: Wikipedia.
AcronymDefinition
VMAT2Vesicular Monoamine Transporter Type 2
References in periodicals archive ?
12) VMAT exists in 2 forms (VMAT1 and VMAT2) that vary in distribution, with VMAT1 expressed mainly in the peripheral nervous system and VMAT2 expressed mainly in monoaminergic cells of the CNS.
To determine if ziram is also toxic to DA neurons in vivo, we utilized a VMAT2:GFP ZF line that expresses GFP driven by the VMAT2 promoter to monitor aminergic neuronal integrity as previously described (Fitzmaurice et al.
Hamer makes clear that, at most, VMAT2 is "a" God gene--not "the" God gene of his book's title.
Therefore, the Pitt researchers posited that increasing VMAT2 protein was the mechanism of action that boosted cognitive performance.
Ingrezza selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors.
VMAT2 is a protein in the brain that packages neurotransmitters for transport and release in presynaptic neurons, concluded the company.
9) The vesicular monoamine transporter (VMAT) exists in 2 isoforms (VMAT1 and VMAT2) that vary in distribution, with VMAT1 expressed mainly in the peripheral nervous system and VMAT2 expressed mainly in monoaminergic cells of the central nervous system.
El equipo de Hammer cncontro que en los individuos con mayor tendencia al misticismo aparecia con mayor frecuencia una variante en el gen VMAT2, la cual implicaba un amnento en el numero de cicrtos receptores que favorecen las experiencias "trascendentales".
He baptized VMAT2 with a provocative phrase: the God gene.
Neurocrine Biosciences, a United States-based biopharmaceutical company, has not met its primary endpoint in the initial phase II Tourette syndrome T-Force GREEN study of INGREZZA (valbenazine), a small molecule VMAT2 inhibitor, it was reported yesterday.
In PD patients, SPECT and PET studies have shown a progressive loss of DAT and VMAT2 and reduced dopa decarboxylase activity using [[.
Avid's second pipeline program, VMAT2 imaging of nigrostriatal degeneration with 18F-AV-133 ("AV-133"), is in Phase I and II clinical trials.